Stock Insights: Medivation, McDonald’s, OmniVision, IntercontinantalExchange June 1st
Medivation, Inc. (NASDAQ:MDVN): JPMorgan believes expectations remain low for Medivation’s enzalutamide’s market share in the large pre-chemo castrate-resistant prostate cancer market. The firm sees the potential for significant upside in the stock and upped its price target for shares to $135 while reiterating an Overweight rating on the stock.
McDonald’s Corp. (NYSE:MCD): BMO Capital believes that the risk/reward ratio of McDonald’s stock going into its report of May comps on June 8 is positive. The firm expects May comps to increase compared with April and it expects the stock to react positively. Nevertheless the firm maintains a Market Perform rating on the shares.
OmniVision Technologies Inc. (NASDAQ:OVTI): Baird believes OmniVision was selected as a second supplier for the iPhone5 rear camera. The firm expects the iPhone5 and potential for the iPad Mini later this year will be key drivers for the shares. Needham recommends buying shares of OmniVision at current levels and maintains a Buy rating on the stock following the company’s Q4 results. The firm says OmniVision’s prospect of winning the main camera socket in the iPhone 5 seems promising, and it believes such a design win could bring substantial upside to the stock.
IntercontinentalExchange, Inc. (NYSE:ICE): After meeting with IntercontinentalExchange’s management, Wells Fargo notes that the company outperformed its peers during the last recession. The firm believes that the company has several secular growth drivers while the fundamentals of its brent crude contracts are strong. Wells maintains an Outperform rating on the shares.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.